HERIZON-BTC-01

A Phase 2b, Open-label, Single-arm Study of Zanidatamab ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers

HERIZON-BTC-01 is a global Phase 2b study of Zanidatamab (also known as ZW25) for the treatment of patients with advanced or metastatic HER2-amplified biliary tract cancers, including intrahepatic and extrahepatic cholangiocarcinoma, and gallbladder cancer.

This multi-centre trial is currently open and recruiting at the following UK locations:

  • Hammersmith Hospital, London (Imperial College) – Dr Harpreet Wassan
  • Royal Free London – Dr Roopinder Gillmore
  • University College Hospital, London – Professor John Bridgewater

And due to open soon at the following UK locations:
The Christie, Manchester – Professor Juan Valle
The Clatterbridge Cancer Centre – Professor Daniel Palmer

For more information, including other European and other locations, please see:
https://clinicaltrials.gov/ct2/show/NCT04466891

Sponsors and collaborators:
Zymeworks Inc.
BeiGene, Ltd.

Back to previous page